Last reviewed · How we verify
Hemay005
Hemay005 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.
Hemay005 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival. Used for Cancer indication (specific type not publicly confirmed).
At a glance
| Generic name | Hemay005 |
|---|---|
| Also known as | Hemay005 tablet, placebo, Phosphodiesterase 4 (PDE4) inhibitors, Mufemilast |
| Sponsor | Ganzhou Hemay Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for Hemay005 are limited in public literature, it is being developed by Ganzhou Hemay Pharmaceutical as an oncology therapeutic in Phase 3 trials. The drug likely works by inhibiting intracellular signaling pathways critical to tumor growth, though the exact molecular target requires confirmation from clinical trial data.
Approved indications
- Cancer indication (specific type not publicly confirmed)
Common side effects
Key clinical trials
- A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD (PHASE2)
- Evaluation the Safety of hemay005 Tablets (PHASE1)
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage (PHASE1)
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment (PHASE1)
- Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets (PHASE1)
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease (PHASE3)
- Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis (PHASE2)
- Bioequivalence Test of Hemay005 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemay005 CI brief — competitive landscape report
- Hemay005 updates RSS · CI watch RSS
- Ganzhou Hemay Pharmaceutical Co., Ltd portfolio CI